Cornea

CMS assigns billing code to support reimbursement for the keratoconus therapy.

All 3 concentrations evaluated in the study were associated with reduced myopia progression.

The trial is evaluating AURN001, a single-administration regenerative cell therapy for corneal edema secondary to corneal endothelial dysfunction.

The study demonstrates that Corynebacterium mastitidis, a bacterium that resides on the ocular surface, can be genetically modified to secrete the anti-inflammatory cytokine interleukin-10.

An off-the-shelf corneal cell injection targets FECD and bullous keratopathy, aiming to restore vision and ease donor shortages.

Michael Raizman, MD, and colleagues evaluated the efficacy and safety of epithelium-on oxygen-enriched corneal CXL in a sub-group analysis of 30 eyes of 22 pediatric patients aged 13 to 17 years.

QoL areas measured included enjoying relationships/life, overall mood, and time spent thinking of eye pain.

Amniotic membrane therapy has been used in refractory cases to protect the ocular surface, modulate inflammation and fibrosis, and promote epithelial healing.

The clinical study will evaluate a noninvasive corneal strengthening procedure designed to reshape the cornea and correct refractive errors in-office without tissue removal.

A recent nonrandomized trial has demonstrated toric IOLs’ efficacy in providing long-term visual outcomes, reducing amblyopia compared to non-toric lenses.

Rachon, OD, FAAO, DipABO, details her SECO 2026 poster presentation, "Treatment of Stage 1 NK Secondary to Acoustic Neuroma Removal with Cryopreserved Amniotic Membrane."

Glaukos noted under the updated labeling, physicians may now re-administer iDose TR more than once in patients who maintain a healthy cornea, as defined by corneal endothelial cell density parameters.

The study looked at 128 eyes in 64 patients before and after they had received the vaccine.

FDA authorizes compassionate use of urcosimod for neuropathic corneal pain, a condition that causes severe pain and sensitivity of the eyes, face, or head.

Bisant A. Labib, OD, FAAO, DipAAO, gives her insights on the causes and management of anterior uveitis during Island Eyes 2026.

Kuzniar's OGSLS 2026 poster presentation provides a follow-up to previous fitting findings for the Zenlens Chroma HOA lens.

The state of the eye’s surface is just as important a factor as accurate measurements when determining the correct IOL.

Jason Jedlicka, OD, overviews his poster, “A Custom Wavefront-Guided Scleral Lens System For Higher Order Aberrations: Real-World Early Experience From a Retrospective Multicenter Case Review.”

A unique case study of HZO featuring Steve Silberberg, OD, DipABO, as the patient.

The PDUFA target action date is June 30, 2026.

NK is more common than recognized; early diagnosis is paramount.

The trial evaluated the safety, efficacy, and tolerability of AURN001 in patients with corneal edema secondary to corneal endothelial dysfunction.

The FDA-approved topical cross-linking treatment aims to simplify keratoconus care while improving patient comfort, with availability expected in early 2026.

The cross-linking system does not disrupt the epithelium, and does not require documentation of disease progression, according to a press release from Epion Therapeutics.